Tirzepatide in Canada: The Complete Research Guide to the Dual-Agonist Peptide
Tirzepatide is the first dual GLP-1/GIP receptor agonist to complete large-scale Phase 3 programmes. It is also one of the most actively researched peptides in Canada right now. This guide covers what tirzepatide is, how its dual-agonist mechanism works, the clinical data from the SURMOUNT and SURPASS programmes, the dosages used in published research, how findings differ between male and female populations, and what to look for when sourcing it. All information is framed for research context only.
What is tirzepatide?
Tirzepatide (LY3298176) is a 39-amino-acid synthetic peptide made by Eli Lilly. It activates two receptors at the same time: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). The molecule includes a C20 fatty di-acid chain that binds to albumin in the blood. This extends its plasma half-life to roughly five days, which is why clinical protocols use once-weekly dosing.
The dual-agonist design is what sets tirzepatide apart from single-receptor GLP-1 compounds like semaglutide. Published trial data from the SURMOUNT programme showed mean reductions exceeding 20% from baseline. Those numbers reshaped the metabolic-research landscape and made tirzepatide one of the most discussed peptides in Canadian research circles.
The dual-agonist mechanism
Tirzepatide engages two incretin receptors that have distinct but complementary metabolic effects. Understanding both is essential for researchers evaluating its pharmacological profile.
GLP-1 receptor
GLP-1 receptor activation enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and influences central appetite-regulation pathways in the hypothalamus and brainstem. This is the same target semaglutide acts on. It is the best-validated incretin pathway in published metabolic literature.
GIP receptor
GIP receptor agonism complements GLP-1 signalling through several mechanisms. GIP acts on pancreatic beta cells to potentiate insulin secretion. Preclinical data also show GIP receptor activity in adipose tissue (body fat), where it may influence lipid metabolism and energy balance. The addition of GIP agonism is what distinguishes tirzepatide from pure GLP-1 compounds. Researchers hypothesise this contributes to the greater magnitude of metabolic effects seen in comparative trials.
Synergistic signalling
By activating both pathways at once, tirzepatide produces pharmacological effects that neither receptor alone achieves to the same degree. The SURPASS head-to-head trial against semaglutide demonstrated statistically superior HbA1c reductions and greater weight changes with tirzepatide. This suggests the dual pathway delivers additive or synergistic benefit in the endpoints measured.
Clinical trial data (SURMOUNT & SURPASS)
Tirzepatide has two major Phase 3 programmes with published data: SURMOUNT (obesity-focused) and SURPASS (type 2 diabetes-focused). Together they represent one of the largest clinical datasets for any incretin-based peptide.
SURMOUNT-1 (2022)
Published in the New England Journal of Medicine, SURMOUNT-1 enrolled 2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus at least one weight-related comorbidity. At 72 weeks, mean weight reductions were:
- 5 mg: −15.0%
- 10 mg: −19.5%
- 15 mg: −20.9%
- Placebo: −3.1%
More than one-third of participants in the 15 mg group achieved ≥25% weight reduction. That threshold had not been reached in any previous pivotal obesity trial.
SURMOUNT-2 (2023)
This trial focused on adults with both obesity and type 2 diabetes (n = 938). At 72 weeks, mean weight reductions reached −12.8% (10 mg) and −14.7% (15 mg) versus −3.2% for placebo. HbA1c reductions were also significant, with >85% of participants achieving HbA1c <7%.
SURPASS-2 (head-to-head vs semaglutide)
SURPASS-2 directly compared tirzepatide (5, 10, and 15 mg) with semaglutide 1 mg in 1,879 adults with type 2 diabetes. At 40 weeks, all three tirzepatide doses produced statistically superior HbA1c reductions and greater mean weight changes compared with semaglutide 1 mg. The 15 mg dose showed a mean weight reduction of −11.2 kg versus −5.7 kg for semaglutide.
SURMOUNT-OSA (2024)
This trial evaluated tirzepatide in adults with obesity and moderate-to-severe obstructive sleep apnoea. At 52 weeks, tirzepatide reduced the apnoea-hypopnoea index (AHI) by approximately 50% and produced mean weight reductions of −18%. These results suggest metabolic effects extend beyond weight and glycaemic endpoints.
Dosages used in published research
The following table summarises dosage tiers evaluated in tirzepatide's major clinical programmes. All figures reflect published trial protocols. This is a research reference, not a prescriptive guide.
| Tier | Weekly dose | Programme | Notes |
|---|---|---|---|
| Starting | 2.5 mg | SURMOUNT & SURPASS | Initial escalation dose; 4-week run-in |
| Escalation 1 | 5 mg | SURMOUNT-1 & SURPASS | First maintenance dose studied; −15% mean weight reduction |
| Escalation 2 | 7.5 mg | SURPASS | Intermediate step in some protocols |
| Mid-range | 10 mg | SURMOUNT-1, -2 | −19.5% mean weight reduction (SURMOUNT-1) |
| Escalation 3 | 12.5 mg | SURPASS | Intermediate step to maximum dose |
| Maximum studied | 15 mg | SURMOUNT-1, -2, -OSA | −20.9% mean weight reduction (SURMOUNT-1) |
All programmes used a gradual escalation protocol with 4-week intervals between dose increases. This table is an educational summary of published clinical-trial data. It is not a dosing recommendation.
Research findings: male vs female populations
Sex-stratified analyses from the SURMOUNT and SURPASS programmes provide important data on how tirzepatide's effects vary between male and female study populations. These findings are relevant for researchers designing sex-aware metabolic studies.
| Parameter | Male populations | Female populations |
|---|---|---|
| Weight reduction (SURMOUNT-1, 15 mg) | Mean −19.2% from baseline | Mean −21.8% from baseline |
| HbA1c reduction (SURPASS-2) | Comparable reductions; men had higher baseline HbA1c | Comparable reductions; women showed slightly greater relative improvement |
| Lean mass preservation | Greater absolute lean mass at baseline; proportional preservation similar | Lower absolute lean mass; proportional preservation similar to men |
| GI tolerability | Nausea reported in approximately 15 to 18% | Nausea reported in approximately 22 to 28% |
| Cardiovascular markers | Reductions in systolic BP and triglycerides observed across doses | Reductions observed; women showed greater improvement in HDL cholesterol |
| Body composition (DXA sub-studies) | Fat mass accounted for roughly 75% of total weight lost | Fat mass accounted for roughly 80% of total weight lost |
Sex-stratified data are drawn from published sub-analyses. Both male and female populations demonstrated clinically meaningful responses across all primary endpoints.
Tirzepatide vs semaglutide vs retatrutide
The following comparison places tirzepatide alongside the other major incretin peptides currently available for Canadian research. Data are drawn from each compound's published Phase 3 results.
| Parameter | Tirzepatide | Semaglutide | Retatrutide |
|---|---|---|---|
| Receptor targets | GLP-1 + GIP (dual) | GLP-1 (single) | GLP-1 + GIP + glucagon (triple) |
| Max studied dose | 15 mg/week | 7.2 mg/week | 12 mg/week |
| Peak weight reduction | −20.9% (SURMOUNT-1) | −20.2% (STEP UP, 7.2 mg) | −24.2% (TRIUMPH-1) |
| Head-to-head data | Superior to sema 1 mg (SURPASS-2) | Baseline comparator | Not yet published |
| Half-life | Approximately 5 days | Approximately 7 days | Approximately 6 days |
| Development stage | Approved (T2D & obesity) | Approved (T2D & obesity) | Phase 3 |
| Admin frequency | Once weekly | Once weekly | Once weekly |
The dual-agonist approach positions tirzepatide between semaglutide's single-receptor design and retatrutide's triple-receptor approach. Its extensive published dataset and head-to-head comparison against semaglutide make it a central reference point in incretin research.
Reconstitution & storage
Reconstitution
Tirzepatide is supplied as a lyophilized (freeze-dried) powder for research purposes. Reconstitute with bacteriostatic water (0.9% benzyl alcohol). A common laboratory preparation uses 1 mL of bacteriostatic water per 5 mg vial, yielding a concentration of 5 mg/mL (5000 mcg/mL). Add the water slowly down the inside wall of the vial. Do not shake. Swirl gently until the powder is fully dissolved. Use our reconstitution calculator for precise concentration math.
Storage
- Lyophilized (unreconstituted): −20 °C for long-term storage, or 2 to 8 °C for up to 24 months. Protect from light and moisture.
- Reconstituted: 2 to 8 °C. Use within 28 days. Do not freeze reconstituted peptide.
- General handling: Use sterile technique. Avoid repeated freeze-thaw cycles. Aliquot into single-use volumes where practical.
How to verify purity: COA & HPLC
With extensive published reference data available for tirzepatide, independent purity verification is straightforward. A per-batch COA (Certificate of Analysis) and HPLC (High-Performance Liquid Chromatography) purity figure are the standard quality checks for any research-grade peptide.
Every 94 Supreme batch ships with its own COA
Third-party tested to HPLC ≥99%, per batch. See the certificates.
Frequently asked questions
Is tirzepatide available in Canada for research?
Yes. Tirzepatide is available as a research peptide in Canada from qualified suppliers such as 94 Supreme Peptides. It is sold strictly for laboratory and research purposes, not for therapeutic use or human consumption.
What purity should I expect?
Reputable Canadian suppliers provide tirzepatide at 99%+ purity, verified by third-party HPLC analysis with per-batch COAs. Always request and review the COA before beginning any research protocol.
How does tirzepatide compare to semaglutide?
Tirzepatide is a dual agonist (GLP-1 + GIP) while semaglutide targets only GLP-1. In the SURPASS-2 head-to-head trial, all three tirzepatide doses (5, 10, 15 mg) produced statistically superior weight reductions and HbA1c reductions compared with semaglutide 1 mg. The additional GIP agonism introduces complementary metabolic signalling not present in semaglutide.
What is the difference between the 5 mg and 15 mg dose in published trials?
In SURMOUNT-1, the 5 mg dose produced mean weight reductions of −15.0% while the 15 mg dose reached −20.9%. Both used the same gradual escalation from 2.5 mg, with 4-week intervals between increases. The dose-response relationship was consistent across trials and study populations.
How should I reconstitute tirzepatide for research?
Add bacteriostatic water slowly down the inside wall of the vial. Do not shake. Swirl gently until dissolved. A typical reconstitution uses 1 mL of bacteriostatic water per 5 mg vial (5 mg/mL). Use our reconstitution calculator for precise concentration math.
Research tirzepatide, tested and shipped from Canada
HPLC ≥99%, a COA for every batch, and 1 to 3 day Xpress Post across Canada.
References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. PubMed
- Garvey WT, Frias JP, Jastreboff AM, et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). The Lancet. PubMed
- Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. PubMed
- Malhotra A, Grunstein RR, Gao M, et al. (2024). Tirzepatide for the treatment of obstructive sleep apnoea and obesity (SURMOUNT-OSA). New England Journal of Medicine. PubMed
- Sattar N, McGuire DK, Pavo I, et al. (2024). Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nature Medicine. Nature Medicine
Citations point to PubMed, The Lancet, and Nature Medicine so you can read the primary sources directly.
For research use only. Not for human or veterinary consumption. This article is educational and summarises published clinical-trial and preclinical research. It is not medical advice. Products are sold strictly as research chemicals.